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Abstract 
Gastric cancer (GC) is one of the most common malignancies worldwide. Better knowledge 
of the changes in gene expression that occur during gastric carcinogenesis may lead to 
improvements in diagnosis, treatment, and prevention. In this study, we screened for genes 
up-regulated in GC by comparing gene expression profiles from microarray and serial 
analysis of gene expression and identified the HOXA10 gene. The aim of the present study 
was to investigate the significance of HOXA10 in GC. Immunohistochemical analysis 
demonstrated that 221 (30%) of 749 GC cases were positive for HOXA10, whereas HOXA10 
was scarcely expressed in non-neoplastic gastric mucosa except in the case of intestinal 
metaplasia. Next, we analyzed the relationship between HOXA10 expression and 
clinicopathologic characteristics. HOXA10 expression showed a significant inverse 
correlation with the depth of invasion, and was observed more frequently in the differentiated 
type of GC than in the undifferentiated type of GC. HOXA10 expression was associated with 
GC with the intestinal mucin phenotype, and correlated with CDX2 expression. Furthermore, 
the prognosis of patients with positive HOXA10 expression was significantly better than in 
the negative expression cases. MTT and wound healing assay revealed that knockdown of 
HOXA10 in GC cells by siRNA-transfection significantly increased viability and motility 
relative to the negative control, indicating that HOXA10 expression inhibits cell growth and 
motility. These results suggest that expression of HOXA10 may be a key regulator for GC 
with the intestinal mucin phenotype. 
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Introduction  
Gastric cancer (GC) is one of the most common human cancers. Cancer develops as a result 
of multiple genetic and epigenetic alterations (1). Better knowledge of the changes in gene 
expression that occur during gastric carcinogenesis may lead to improvements in diagnosis, 
treatment, and prevention. Identification of novel biomarkers for cancer diagnosis and novel 
targets for treatment are major goals in this field (2). We previously performed several large 
scale gene expression studies using array-based hybridization (3), serial analysis of gene 
expression (SAGE) (4,5) and the Escherichia coli ampicillin trap (CAST) method (6), and 
identified several genes including regenerating islet-derived family, member 4 (REG4, which 
encodes REG IV) (7,8), palate, lung, and nasal epithelium carcinoma-associated protein 
(PLUNC) (9), GJB6 (encoding connexin 30) (10) and DSC2 (encoding desmocollin 2) (11). 
These results indicated that these methods are useful for identification of novel genes 
associated with GC; however, such alterations cannot completely explain the pathogenesis of 
GC. In our previous study, the 20 genes showing the greatest increase in expression on the 
microarray were quite different from those obtained by SAGE (9). Therefore, we performed 
gene expression profiling using Affymetrix GeneChip Arrays of GC samples previously 
analyzed by SAGE, and identified several candidate GC-associated genes. Among these 
candidate genes, the homeobox A10 (HOXA10) gene is up-regulated in all samples. To date, 
little is known about the role of HOXA10 in human GC. 
The HOX genes are important regulators of embryonic morphogenesis and 
differentiation and control normal development patterning along the antero-posterior axis. 
They contain a common DNA motif of a sequence of 183 nucleotides, encoding a region of 
61 amino acids called the homeodomain, their sequences being the basis for classification into 
different subsets (12). The homeodomain is responsible for recognizing and binding to 
sequence-specific DNA motifs and cis-regulates the transcription of genes relevant to 
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formation of specific segmental architecture. In humans, 39 HOXs have been identified that 
are spread among four different clusters located on four separate chromosomes: 7 (HOXA), 
17 (HOXB), 12 (HOXC) and 2 (HOXD) (13). A putative role of HOXs in malignant 
processes has been well documented in leukemia. They participate in myeloid cell 
differentiation and proliferation (14,15). HOXA10 and HOXA9 are associated with acute 
myeloid leukemia (AML) and mixed lineage leukemia (MLL) fusion genes (16). HOXA10 
controls uterine organogenesis during embryonic development and endometrial differentiation 
in adults (17). Deregulation of HOXA10 correlates with progression of endometrial 
carcinoma (18). CDX2 has been reported to be an upstream regulator for HOXA10 in 
myeloid cells and participates in leukemogenesis (19). However, the exact pathogenic 
mechanisms associated with HOXA10 in stomach carcinogenesis remain obscure. 
The present study represents the first detailed analysis of HOXA10 expression in 
GC. To clarify the pattern of expression and localization of HOXA10 in GC, we performed 
immunohistochemical analysis of surgically resected GC samples and analyzed the 
association between HOXA10 and various markers including the gastric/intestinal phenotypes 
(MUC5AC, MUC6, MUC2 and CD10), CDX2, -catenin, EGFR and p53. Furthermore, we 
also studied the relationship between HOXA10 expression and patient prognosis and the 
effect of HOXA10 on cell growth, motility and invasion.
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Materials and methods 
Tissue samples 
For microarray analysis, 2 primary GC samples (W226T, 59-year-old man, T1N0M0, stage I, 
well differentiated adenocarcinoma; W246T, 44-year-old man, T2N2M0, stage III, well 
differentiated adenocarcinoma) and corresponding non-neoplastic mucosa were used. These 
GC samples were analyzed previously by SAGE for comprehensive gene expression profiling 
(5). For quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis, 38 
GC samples and corresponding non-neoplastic mucosa samples were used. The samples were 
obtained during surgery at the Hiroshima University Hospital. We confirmed microscopically 
that the tumor specimens were predominantly (>50%) cancer tissue. Samples were frozen 
immediately in liquid nitrogen and stored at -80˚C until use. Samples of normal brain, spinal 
cord, heart, skeletal muscle, lung, stomach, small intestine, colon, liver, pancreas, kidney, 
uterus, bone marrow, spleen, peripheral leukocytes, and trachea were purchased from 
Clontech (Palo Alto, CA). For immunohistochemical analysis, we used archival 
formalin-fixed, paraffin-embedded tissues from 749 patients (480 men and 269 women; age 
range, 29-88 years; mean, 70years) who had undergone surgical excision for GC at the 
Hiroshima University Hospital or affiliated hospitals. The 749 GC cases were histologically 
classified as 429 differentiated type (papillary adenocarcinoma or tubular adenocarcinoma) 
and 320 undifferentiated type (poorly differentiated adenocarcinoma, signet-ring cell 
carcinoma or mucinous adenocarcinoma), according to the Japanese Classification of Gastric 
Carcinomas (20). Tumor staging was carried out according to the TNM classification. 
Because written informed consent was not obtained, identifying information for all samples 
was removed before analysis for strict privacy protection. This procedure was in accordance 
with the Ethical Guidelines for Human Genome/Gene Research enacted by the Japanese 
Government. 
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Microarray analysis 
Gene expression profiles of tissue samples were analyzed by genome-wide microarrays as 
described previously (21). Affymetrix GeneChip Human Genome U133Plus 2.0 arrays 
(Affymetrix, Santa Clara, CA) were used. Each transcript on this array is represented by a set 
of 11 probe pairs, called the probe set. The array contains >54,000 probe sets, representing 
47,400 transcripts, including 38,500 genes. Five micrograms of total RNA were used to 
prepare antisense biotinylated RNA with One-cycle Target Labeling and Control Reagent 
(Affymetrix) according to the manufacturer's instructions. In brief, first-stranded cDNA was 
synthesized with a T7-RNA polymerase promoter-attached oligo(dT) primer followed by 
second-stranded cDNA synthesis. This cDNA was purified and served as a template in the 
subsequent in vitro T7-transcription (IVT). The IVT reaction was carried out in the presence 
of T7 RNA polymerase and biotinylated UTP for cRNA production. The biotinylated cRNAs 
were then cleaned up and fragmented. The fragmented, biotinylated cRNA was hybridized to 
the array (45°C for 16 hours). The procedures for staining, washing, and scanning of arrays 
were carried out according to the instructions in the Affymetrix technical manual. The 
expression value (average difference, AD) of each probe was calculated with GeneChip 
Operating Software Version 1.1 (Affymetrix). The mean of AD values in each experiment was 
1000 to reliably compare variable multiple arrays. 
 
Quantitative RT-PCR analysis 
Total RNA was extracted with an RNeasy Mini Kit (Qiagen, Valencia, CA), and 1 µg of total 
RNA was converted to cDNA with a First Strand cDNA Synthesis Kit (Amersham 
Biosciences, Piscataway, NJ). Quantitation of HOXA10 mRNA levels in human tissue 
samples was done by real-time fluorescence detection as described previously (22). PCR was 
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performed with a SYBR Green PCR Core Reagents Kit (Applied Biosystems, Foster City, 
CA). The HOXA10 primer sequences were 5'-AGA TAT TGT CCT AAG TGT CAA GTC 
CTG A-3' and 5'-GCC ATT TCG AGC AGT GGG-3'. Real-time detection of the emission 
intensity of SYBR Green bound to double-stranded DNA was performed with an ABI PRISM 
7700 Sequence Detection System (Applied Biosystems) as described previously (23). 
ACTB-specific PCR products were amplified from the same RNA samples and served as 
internal controls. We calculated the ratio of HOXA10 mRNA levels between GC tissue (T) 
and corresponding non-neoplastic mucosa (N). T/N ratios of more than 2.0 were considered to 
indicate up-regulation. 
 
Antibodies 
Goat polyclonal anti-HOXA10 antibody was purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA). We used four antibodies for analysis of the GC mucin phenotypes: mouse 
monoclonal anti-MUC5AC (Novocastra, Newcastle, UK) as a marker of gastric foveolar 
epithelial cells, mouse monoclonal anti-MUC6 (Novocastra, Newcastle, UK) as a marker of 
pyloric gland cells, mouse monoclonal anti-MUC2 (Novocastra, Newcastle, UK) as a marker 
of goblet cells in the small intestine and colorectum, mouse monoclonal anti-CD10 
(Novocastra, Newcastle, UK) as a marker of microvilli of absorptive cells in the small 
intestine and colorectum. In addition, we used mouse monoclonal anti-CDX2 (BioGenex, San 
Ramon, CA) as a marker of differentiation of intestinal epithelial cells, mouse monoclonal 
anti--catenin (BD Biosciences, San Jose, CA), mouse monoclonal anti-EGFR (Novocastra, 
Newcastle, UK) and mouse monoclonal anti-p53 (Novocastra, Newcastle, UK). 
 
Western blot analysis 
For western blot analysis, tissue samples or cells were lysed as described previously (24). The 
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lysates (40 µg) were solubilized in Laemmli sample buffer by boiling and then subjected to 
12% SDS-polyacrylamide gel electrophoresis followed by electrotransfer onto a nitrocellulose 
filter. Peroxidase-conjugated anti-goat IgG was used in the secondary reaction. 
Immunocomplexes were visualized with an ECL Western Blot Detection System (Amersham 
Biosciences). -actin antibody (Sigma Chemical) was also used as a loading control. 
 
Immunohistochemistry 
A Dako LSAB Kit (Dako, Carpinteria, CA) was used for immunohistochemical analysis. In 
brief, sections were pretreated by microwave treatment in citrate buffer for 15 min to retrieve 
antigenicity. After peroxidase activity was blocked with 3% H2O2-methanol for 10 min, 
sections were incubated with normal goat serum (Dako, Carpinteria, CA) for 20 min to block 
non-specific antibody binding sites. Sections were incubated with the following primary 
antibodies: anti-HOXA10 (diluted 1 : 50), anti-MUC5AC (1 : 50), anti-MUC6 (1 : 50), 
anti-MUC2 (1 : 50), anti-CD10 (1 : 50), anti-CDX2 (1 : 20), anti--catenin (1 : 50), 
anti-EGFR (1 : 50) and anti-p53 (1 : 50). Sections were incubated with primary antibody for 1 
h at 25 °C, followed by incubations with biotinylated anti-rabbit/mouse IgG and peroxidase 
labeled streptavidin for 10 min each. Staining was completed with a 10-min incubation with 
the substrate-chromogen solution. The sections were counterstained with 0.1% hematoxylin. 
Each molecule was classified according to the percentage of stained cancer cells. Expression 
was considered to be "negative" if <10% of cancer cells were stained. When at least 10% of 
cancer cells were stained, the result of immunostaining was considered "positive." 
 
Phenotypic analysis of GC 
GC cases were classified into four phenotypes: gastric phenotype, intestinal phenotype, 
gastric and intestinal mixed phenotype, and unclassified phenotype. The criteria (25) for 
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classification of gastric phenotype and intestinal phenotype were as follows. GCs in which 
more than 10% of the cells displayed the gastric or intestinal epithelial cell phenotype were 
gastric phenotype or intestinal phenotype cancers, respectively. Those sections that showed 
both gastric and intestinal phenotypes were classified as gastric and intestinal mixed 
phenotype, and those that lacked both the gastric and the intestinal phenotypes were classified 
as the unclassified phenotype. 
 
GC cell lines 
Nine cell lines derived from human GC were used. The TMK-1 cell line was established in 
our laboratory from a poorly differentiated adenocarcinoma (26). Five GC cell lines of the 
MKN series (MKN-1, adenosquamous cell carcinoma; MKN-7; MKN-28; MKN-74, 
well-differentiated adenocarcinoma; and MKN-45, poorly differentiated adenocarcinoma) 
were kindly provided by Dr Toshimitsu Suzuki (Fukushima Medical University School of 
Medicine)(27,28). KATO-III, HSC-39 and HSC-57 cell lines were kindly provided by Dr 
Morimasa Sekiguchi (University of Tokyo)(29) and Dr Kazuyoshi Yanagihara (Yasuda 
Women’s University)(30), respectively. All cell lines were maintained in RPMI 1640 (Nissui 
Pharmaceutical Co, Ltd, Tokyo, Japan) containing 10% fetal bovine serum (BioWhittaker, 
Walkersville, MD) in a humidified atmosphere of 5% CO2 and 95% air at 37 °C. 
 
RNA interference (RNAi) and overexpression of HOXA10 in cell growth, wound healing 
assay and in vitro invasion assay 
To knockdown the endogenous HOXA10, RNAi was performed. Short interfering RNA 
(siRNA) oligonucleotides for HOXA10 and a negative control were purchased from 
Invitrogen (Carlsbad, CA). Three independent oligonucleotides were used for HOXA10 
siRNA as follows: a HOXA10 siRNA1 sequence, 5'-GAG UUU CUG UUC AAU AUG UAC 
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CUU A-3'; a HOXA10 siRNA2 sequence, 5'-CCG GGA GCU CAC AGC CAA CUU UAA U 
-3'; and a HOXA10 siRNA3 sequence, 5'-CGG CAA AGA GUG GUC GGA AGA AGC G -3'. 
Transfection was performed using Lipofectamine RNAiMAX (Invitrogen) as described 
previously (31). Briefly, 60 pmol of siRNA and 10 µL of Lipofectamine RNAiMAX were 
mixed in 1 mL of RPMI medium (10 nmol/L final siRNA concentration). After 20 min of 
incubation, the mixture was added to the cells and these were plated on dishes for each assay. 
Forty-eight hours after transfection, cells were analyzed for all experiments. The cells were 
seeded at a density of 2,000 cells per well in 96-well plates. For constitutive expression of 
HOXA10, cDNA was amplified by PCR and subcloned into pcDNA 3.1 (Invitrogen). 
Transient transfection was carried out with the FuGENE6 Transfection Reagent (Roche 
Diagnostics, Indianapolis, IN). Cell growth was monitored after 1, 2 and 4 days by the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (32). To evaluate 
cell motility, a wound healing assay was performed. Cells grown to subconfluence were 
scraped with a sharp edge to make a cell-free area. Cells migrating into the scraped area were 
observed and photographs were taken every 12 hours after scraping. Modified Boyden 
chamber assays were performed to examine invasiveness. Cells were plated at 10,000 cells 
per well in RPMI 1640 medium plus 1% serum in the upper chamber of a Transwell insert (8 
µm pore diameter; Chemicon, Temecula, CA) coated with Matrigel. Medium containing 10% 
serum was added in the bottom chamber. After 1 and 2 days, cells in the upper chamber were 
removed by scraping, and the cells remaining on the lower surface of the insert were stained 
with CyQuant GR dye to assess the number of cells.  
 
Statistical methods 
Correlations between clinicopathologic parameters and HOXA10 staining were analyzed by 
Fisher’s exact test. Kaplan-Meier survival curves were constructed for HOXA10, MUC5AC, 
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MUC6, MUC2, CD10 or CDX2-positive and -negative patients to compare survival between 
both groups. The differences in survival curves between groups were tested for statistical 
significance by the log-rank test (33). P values of less than 0.05 were considered statistically 
significant. Univariate and multivariate Cox regression was used to evaluate the associations 
between clinical covariates and cancer-specific mortality. Hazard ratio (HR) and 95% 
confidence interval (CI) were estimated from Cox proportional hazard models. For all 
analyses, age was treated as a categorical variable (65 years of age and less versus more than 
65 years of age). For final multivariable Cox regression models, all variables were included 
that were moderately associated (P < 0.05) with cancer-specific mortality.  
 
 
Results 
Identification of up-regulated genes in GC through microarray analysis 
To identify genes with increased expression in GC, we performed microarray analysis. The 
gene expression profiles obtained from the two primary GC samples (W226T, W246T) and 
the corresponding non-neoplastic gastric mucosa samples were compared. The top 20 genes 
that showed higher expression in the GC samples than in the corresponding non-neoplastic 
gastric mucosa sample by microarray analysis are each listed in Table 1. The gene showing 
the greatest increase in expression in both GC samples by microarray was HOXA10. In our 
previous report analyzing the PLUNC gene, the HOXA10 gene had the 9th greatest increase in 
expression in poorly differentiated adenocarcinoma of the stomach (P208T) in the microarray 
analysis (9). We reported a list of the 20 genes with the greatest increase in expression in 
these three GC samples compared with normal stomach by SAGE analysis (5). We noted that 
the 20 most up-regulated genes identified by microarray were quite different from those 
identified by SAGE, indicating that genes up-regulated in GC are not always detected with 
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SAGE. We then reviewed the expression level of HOXA10 with our SAGE data and found 
that the SAGE tag sequence of HOXA10, CATAAAAGGG, did not appear in the W226T, 
W246T and P208T SAGE data. Because expression of HOXA10 has not been investigated in 
GC we therefore decided to analyze it. 
 
mRNA expression of HOXA10 in systemic normal tissues and GC tissues  
Quantitative RT-PCR was performed to investigate the specificity of HOXA10 expression in 
16 normal organs. As shown in Figure 1A, HOXA10 expression was clearly detected in 
normal skeletal muscle and to a lesser extent in uterine endometrium, kidney and large 
intestine. The expression of HOXA10 was detected at low levels, or not at all, in other normal 
organs, including stomach tissue. These results are consistent with those in a previous report 
(18). Next, we analyzed the expression of HOXA10 in 38 GC tissue samples and 38 
corresponding non-neoplastic mucosa samples by quantitative RT-PCR. Of the 38 GC cases, 
expression of HOXA10 was up-regulated in 27 (71%) (Figure 1B). mRNA expression levels 
of HOXA10 showed no correlations with T grade (depth of tumor invasion), N grade (degree 
of lymph node metastasis), or the tumor stage.  
 
Immunohistochemical analysis of HOXA10 in GC and its correlation with 
clinicopathological parameters 
To test the specificity of the anti-HOXA10 antibody, western blotting of lysates from 9 GC 
cell lines was carried out (Figure 2A). The anti-HOXA10 antibody detected a single band of 
approximately 41-kD on western blots of MKN-45, MKN-74, TMK-1, HSC-39 and HSC-57 
cell extracts. Uterus tissue was used as a positive control of HOXA10 expression. Using this 
antibody, we performed immunostaining of HOXA10 in 749 GC and corresponding 
non-neoplastic gastric mucosa samples (Figure 1). HOXA10 expression was detected in 221 
Sentani K et al. 13 
 
of the 749 GCs (30%) and was found in the nucleus of both early GC and advanced GC. 
Histologically, expression of HOXA10 was observed more frequently in the differentiated 
type of GC than in the undifferentiated GC (P < 0.0001) (Table 2). In non-neoplastic gastric 
mucosa, HOXA10 was scarcely expressed in normal gastric mucosa, while it was often 
observed in the nucleus of intestinal metaplasia (Figure 1). Next, we analyzed the relationship 
between HOXA10 expression and clinicopathologic characteristics. HOXA10 staining 
showed a significant inverse correlation with the depth of invasion (P < 0.0001). There was 
no significant association between HOXA10 staining and other parameters (age, sex, N grade, 
M grade or stage). 
 
Association of HOXA10 expression with the intestinal mucin phenotype of GC 
We investigated the association between HOXA10 expression and various markers 
determining the gastric/intestinal mucin phenotypes. Out of the 749 cases examined, each 
molecule was detected in 437 (58%) cases for MUC5AC, 63 (8%) cases for MUC6, 179 
(24%) cases for MUC2, and 70 (9%) cases for CD10. The 749 GC cases were classified into 
four phenotypes: 297 (40%) were the gastric phenotype, 172 (23%) were the gastric and 
intestinal mixed phenotype, 130 (17%) were the intestinal phenotype, and 150 (20%) were the 
unclassified phenotype. Positive expression of HOXA10 was significantly more frequent in 
MUC2-positive cases than MUC2-negative cases (P < 0.0001) (Figure 1 and Table 3). 
HOXA10 expression occurred more frequently in the intestinal phenotype and the gastric and 
intestinal mixed phenotype than in the gastric phenotype and the unclassified phenotype (P = 
0.0004). On the other hand, CDX2 was detected in 195 of the 749 (26%) cases, and positive 
expression of HOXA10 was significantly more frequent in CDX2-positive cases than 
CDX2-negative cases (P = 0.0003) (Figure 1 and Table 3). The other molecules were detected 
in 245 (33%) cases for -catenin, 99 (13%) cases for EGFR, and 257 (34%) cases for p53. 
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There was no clear relationship between expression of HOXA10 and these markers. 
 
Relationship between expression of HOXA10 in GC and patient prognosis 
We also examined the relationship between survival and expression of HOXA10, CDX2 and 
mucins (MUC5AC, MUC6, MUC2 and CD10) in 103 GCs. The prognosis of patients with 
positive HOXA10 expression was significantly better than in the negative cases (Figure 1I) (P 
= 0.0047, log-rank test). The expression of the other molecules had no significant effect on 
the prognosis of patients (CDX2, P = 0.1426; MUC5AC, P = 0.3936; MUC6, P = 0.9835; 
MUC2, P = 0.4996; CD10, P = 0.27). In order to evaluate the potential for HOXA10 
expression as a prognostic classifier, both univariate and multivariate Cox proportional 
hazards analysis was used to further evaluate the association of HOXA10 expression with 
cancer-specific mortality (Table 4). In univariate analysis, negative expression of HOXA10 
(HR, 0.41; 95% CI, 0.22-0.78; P = 0.006) and the TNM stage (HR, 6.13; 95% CI, 2.84-13.3; 
P < 0.0001) were associated with survival. In the multivariate model, negative expression of 
HOXA10 expression and TNM stage were independent predictors of survival in patients with 
GC (Table 4).  
 
Effect of HOXA10 up-regulation and down-regulation on cell growth, cell motility and 
invasive activity 
HOXA10 staining showed a significant inverse correlation with the depth of invasion, 
suggesting that HOXA10 may be associated with tumor progression. However, the biological 
significance of HOXA10 in GC has not been studied. To investigate the possible involvement 
of HOXA10 on cell growth, an MTT assay was performed on the 4th day after HOXA10 
siRNA or control scrambled siRNA transfection in the MKN-45 and MKN-74 cell lines, and 
MKN-28 cell line transfected with HOXA10 expression vector (pcDNA-HOXA10) or empty 
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vector. At first, we checked the up-regulation or down-regulation of HOXA10 from day 0 to 
day 4, using western blotting or quantitative RT-PCR analysis (Figure 2B). Both HOXA10 
siRNA-transfected MKN-45 and MKN-74 cells showed significantly increased viability 
relative to negative control cells, while cell viability of pcDNA-HOXA10 were not different 
from those of a negative control vector (Figure 2C). Next, effects of HOXA10 expression on 
migration potency were determined using a wound healing assay. Both HOXA10 
siRNA-transfected MKN-45 and MKN-74 cells migrating into the scratched area were 
significantly more than negative control cells (Figure 2D), while cell motility of 
pcDNA-HOXA10 was not different from those of a negative control vector (data not shown). 
In addition, a transwell invasion assay was performed in the MKN-45 and MKN-74 cell line 
to determine the possible role of HOXA10 in the invasiveness of GC cells. Invasion ability 
was not significantly different between HOXA10 knockdown GC cells and control GC cells 
(data not shown). These results indicate that HOXA10 inhibits cell growth and cell motility, 
but not invasion in GC cells. 
 
 
Discussion 
In the present study, we studied the gene expression profile using microarray data of GC 
samples that were previously analyzed by SAGE (5), and identified that the HOXA10 gene 
was up-regulated in all samples. Quantitative RT-PCR in 38 GC samples revealed that 
HOXA10 was overexpressed in more than 70% of GCs. Because up-regulation of HOXA10 
was identified by microarray and quantitative RT-PCR analysis of bulk GC tissues, 
immunohistochemistry was required to determine whether cancer cells truly express 
HOXA10. Immunohistochemical analysis revealed that HOXA10-positive cancer cells were 
detected in 221 (30%) of the 749 GC cases. HOXA10 was frequently expressed in 
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MUC2-positive GC cases, and HOXA10 expression was observed at high levels in GC with 
intestinal mucin phenotype. Ectopic CDX2 expression plays an important role in the 
development of GC with intestinal phenotype (34,35). Here we also showed that HOXA10 
expression was correlated with CDX2 expression in GC tissue. A previous report indicated 
that overexpression of CDX2 with the N-terminal transactivation domain up-regulated 
HOXA10 gene expression in murine bone marrow progenitors (19). Taken together, 
expression of HOXA10, in addition to CDX2, may be a key factor mediating the development 
of GC with the intestinal mucin phenotype. 
In non-neoplastic gastric mucosa, HOXA10 was scarcely expressed in normal 
gastric mucosa. However, we often observed nuclear accumulation of HOXA10 in intestinal 
metaplasia. The findings that HOXA10 expression is observed in intestinal metaplasia as well 
as in GC with the intestinal phenotype imply that this change occurs at an early stage of 
stomach carcinogenesis. Aberrations of DNA methylation are now believed to be an important 
epigenetic alteration occurring early in many cancers (36). In addition it has been reported 
that there is a relationship between aberrant methylation of HOXA10 and its protein 
expression in ovarian cancer and endometrial cancer (18,37). We speculated that aberrant 
promoter hypomethylation of the HOXA10 gene leads to high expression of HOXA10 in GC.  
In immunohistochemical analysis, there was a significant inverse correlation 
between HOXA10 expression and tumor progression. In addition, the prognosis of patients 
with positive HOXA10 expression was significantly better than that of negative cases. The 
previous reports showed that enforced expression of HOXA10 in endometrial carcinoma cells 
inhibited invasive behavior through down-regulating Snail expression and inducing 
E-cadherin expression (18), and that increased HOXA10 in breast cancer cells regulated p53 
expression towards reduction of invasiveness (38). HOXA10 was reported to bind to the p21 
promoter and activate p21 transcription, resulting in cell cycle arrest and differentiation in 
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differentiating myelomonocytic cells (15). Furthermore, Sugimoto et al. reported that the 
expression of HOXA10 has an important role in apoptosis induction of chronic myelogenous 
leukemia cells treated with tyrosine kinase inhibitors (39). In the present study, knockdown of 
HOXA10 by siRNA had an effect on cell growth and cell motility in the GC cell line, but not 
on cell invasion. Furthermore, we observed a higher expression of HOXA10 in the 
differentiated type of GC compared with the undifferentiated type. This may reflect a loss of 
ability to express this protein along with a decrease in histological differentiation in neoplastic 
cells. Once malignant formation is completed, HOXA10 might deregulate the progression of 
GC. It is possible that loss of HOXA10 expression could lead to tumor progression by 
promoting epithelial-mesenchymal transition (18). There was no clear relationship between 
expression of HOXA10 and -catenin, EGFR and p53. Further studies should be performed in 
the near future to elucidate the tissue specificity of the detailed pathways involving HOXA10. 
In the present study, we compared gene expression profiles of GC samples analyzed 
by microarray analysis and SAGE. The 20 genes showing the greatest increase in expression 
on the microarrays were quite different from those obtained with the SAGE library. 
Investigation of the difference between microarray analysis and SAGE is beyond the scope of 
the present study and will be described elsewhere. 
In summary, we demonstrated that HOXA10 is frequently up-regulated in GC with 
the intestinal mucin phenotype and HOXA10 expression correlates with favorable survival in 
patients with GC. HOXA10 expression may be a key factor mediating the biological behavior 
of the intestinal phenotype of GC. 
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Table 1.  The 20 most up-regulated genes in both early and advanced GC by microarray 
analysis 
Early GC Advanced GC 
 Intensity   Intensity 
Symbol W226T1 Non-neoplastic 
mucosa 
Fold Symbol W246T2 Non-neoplastic 
mucosa 
Fold
LOC339751 6514 7 931 FGFR2 25747 25 1030
SLC19A3 6398 17 376 NOX1 2765 3 922 
HOXA13 2619 9 291 IMP-3 5772 11 525 
C14orf105 1104 5 221 HOXA10 6255 16 391 
ADH4 41503 213 195 TMEM16C 1840 5 368 
HOXA10 2789 15 186 FLJ21545 3756 13 289 
LEFTY1 34166 249 137 KCNJ3 5488 29 189 
ZIC2 400 4 100 CaMKllN 
alpha 
1928 12 161 
SPRR1A 1083 12 90 FLJ38736 3732 29 129 
CPS1 92949 1093 85 NTS 17320 141 123 
CST1 3014 36 84 PPL8 615 5 123 
LOC136288 128 2 64 PCLO 1148 10 115 
FLJ12971 256 4 64 CHM 111 1 111 
FLJ42567 1952 32 61 FLJ42567 3498 33 106 
LOC338759 175 3 58 MGC32871 26808 271 99 
LOC196264 172 3 57 CDX1 9581 97 98 
NYD-SP20 165 3 55 IMAGE:480
6358 
22819 235 97 
ADH6 4558 86 53 MGC48998 2287 24 95 
CaMKIIN alpha 612 12 51 TFF3 45055 502 90 
CEACAM7 306 6 51 AFP 9018 104 87 
1W226T: 59-year-old man, T1N0M0, stage I, well-differentiated adenocarcinoma. 
2W246T: 44-year-old man, T2N2M0, stage III, well-differentiated adenocarcinoma. 
GC, gastric cancer. 
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Table 2.  Relation between HOXA10 expression and clinicopathologic parameters in 
749 cases of GC 
 HOXA10 expression  
Factor Positive (n = 221) Negative (n = 528) P value 
Age    
 ≤65 years (n = 359) 95 (26%) 264 NS 
 >65 years (n = 390) 126 (32%) 264  
Sex    
 Male (n = 480) 137 (29%) 343 NS 
 Female (n = 269) 84 (31%) 185  
T grade1    
 T1/T2 (n = 608) 216 (36%) 392 < 0.0001 
 T3/T4 (n = 141) 5 (4%) 136  
N grade1    
 N0 (n = 433) 131 (30%) 302 NS 
 N1/N2/N3 (n = 316) 90 (28%) 226  
M grade1    
 M0 (n = 742) 217 (29%) 525 NS 
 M1 (n = 7) 4 (57%) 3  
Stage1    
 Stage 0/I (n = 425) 130 (31%) 295 NS 
 Stage II/III/IV (n = 324) 91 (28%) 233  
Histology2    
 Differentiated (n = 429) 152 (35%) 277 < 0.0001 
 Undifferentiated (n = 320) 69 (22%) 251  
P-values were calculated by Fisher’s exact test. 
1Tumor stage was classified according to the criteria of the International Union Against 
Cancer TNM classification of malignant tumors. 
2Histology was determined according to the Japanese Classification of Gastric Cancer. 
GC, gastric cancer; NS, not significant. 
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Table 3.  Relation between HOXA10 expression and various molecules 
including mucin-related markers in 749 cases of GC 
 
 HOXA10 expression  
Molecule Positive (221) Negative (528) P value 
MUC5AC    
 Positive 140 (32%) 297 NS 
 Negative 81 (26%) 231  
MUC6    
 Positive 22 (35%) 41 NS 
 Negative 199 (29%) 487  
MUC2    
 Positive 79 (44%) 100 < 0.0001 
 Negative 142 (25%) 428  
CD10    
 Positive 17 (24%) 53 NS 
 Negative 204 (30%) 485  
CDX2    
 Positive 78 (40%) 117 0.0003 
 Negative 143 (26%) 411  
β-catenin    
 Positive 69 (28%) 176 NS 
 Negative 152 (30%) 352  
EGFR    
 Positive 32 (32%) 67 NS 
 Negative 189 (29%) 461  
p53    
 Positive 79 (31%) 178 NS 
 Negative 142 (29%) 350  
P values were calculated by Fisher’s exact test. 
GC, gastric cancer; NS, not significant; CDX2, caudal-related homeobox gene 
2; EGFR, epidermal growth factor receptor. 
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Table 4.  Univariate and multivariate Cox regression analysis of HOXA10 expression and 
overall survival in 134 cases of GC 
Factor 
Univariate analysis Multivariate analysis 
HR (95% CI) P value HR (95% CI) P value 
Age     
 ≤65 years 1 (Ref.) 0.15   
 >65 years 1.82 (0.81-4.12)    
Sex     
 Female 1 (Ref.) 0.29   
 Male  1.39 (0.75-2.58)    
HOXA10     
 Negative 1 (Ref.) 0.006 1 (Ref.) 0.0044 
 Positive 0.41 (0.22-0.78)  0.39 (0.21-0.75)  
CDX2     
 Negative 1 (Ref.) 0.15   
 Positive 0.58 (0.28-1.21)    
MUC5AC     
 Negative 1 (Ref.) 0.39   
 Positive 0.76 (0.41-1.42)    
MUC6     
 Negative 1 (Ref.) 0.98   
 Positive 1.01 (0.36-2.83)    
MUC2     
 Negative 1 (Ref.) 0.51   
 Positive 0.77 (0.35-1.66)    
CD10     
 Negative 1 (Ref.) 0.27   
 Positive 1.54 (0.71-3.32)    
TNM stage1     
 Stage 0/I 1 (Ref.) < 0.0001 1 (Ref.) 0.0044 
 Stage II/III/IV 6.13 (2.84-13.3)  6.45 (2.94-14.1)  
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Histology2     
 Differentiated 1 (Ref.) 0.29   
 Undifferentiated 1.41 (0.75-2.63)    
1TNM stage was classified according to the criteria of the International Union Against Cancer 
TNM classification of malignant tumors. 
2Histological type was determined according to the Japanese Classification of Gastric Cancer. 
GC, gastric cancer; HR, hazard ratio; CI, confidence interval; NS, not significant; CDX2, 
caudal-related homeobox gene 2. 
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Fig. 1.  
Quantitative RT-PCR analysis of HOXA10 in systemic normal tissues, gastric cancer (GC) 
tissues and corresponding non-neoplastic mucosa. (A) Clear HOXA10 expression is present in 
normal skeletal muscle, uterus, kidney and colon. The units are arbitrary. (B) Fold-change 
indicates the ratio of HOXA10 mRNA level in GC (T) to that in the corresponding 
non-neoplastic mucosa (N). Expression of HOXA10 was up-regulated (T/N < 2) in 27 (71%) 
of 38 GC cases. Immunohistochemical staining of HOXA10, CDX2 and MUC2 in gastric 
cancer (GC) and intestinal metaplasia (C-H), and the relationship between HOXA10 
expression and patient prognosis (I). HOXA10 was detected in the nucleus of both 
differentiated (C, F) and undifferentiated GC (G), but not in non-cancerous epithelium, except 
for intestinal metaplasia (H). The prognosis of patients with positive HOXA10 expression 
was significantly better than in the negative cases (I) (P = 0.0047, log-rank test). 
 
 
Fig. 2.  
Effect of HOXA10 up-regulation and down-regulation on cell growth and cell motility. The 
anti-HOXA10 antibody detected an approximately 41-kD band on western blots of MKN-45, 
MKN-74, TMK-1, HSC-39 and HSC-57 cell extracts. Uterus tissue was used as a positive 
control of HOXA10 expression (A). Western blotting and quantitative RT-PCR analysis of 
HOXA10 expression in MKN-45 and MKN-74 cell lines with HOXA10 siRNA or control 
scrambled siRNA transfection (Day 0-4), and MKN-28 cell line transfected with HOXA10 
cDNA or empty vector (Day 0) (B). To investigate the possible involvement of HOXA10 on 
cell growth, an MTT assay was performed on the 4th day after siRNA or HOXA10 expression 
vector transfection (C). Both HOXA10 siRNA-transfected MKN-45 and MKN-74 cells 
showed significantly increased viability relative to control scrambled siRNA-transfected cells. 
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Next, effects of HOXA10 expression on migration potency were determined using a wound 
healing assay (D). Both HOXA10 siRNA-transfected MKN-45 and MKN-74 cells migrating 
into the scratched area were significantly more than negative control cells. 


